Alpha-fetoprotein testing for hepatocellular carcinoma may not be helpful in nonalcoholic steatohepatitis

Linda L. Wong, Christopher J. Kim, Sandi A. Kwee, Brenda Y. Hernandez

Department of Medicine, University of Hawaii, John A. Burns School of Medicine, Honolulu, USA.
Department of Surgery, University of Hawaii, John A. Burns School of Medicine, Honolulu, USA.
University of Hawaii Cancer Center, Honolulu, USA.

DOI: 10.4236/ojgas.2013.31008                

Abstract

Background & Objectives: Diagnosing hepatocellular carcinoma (HCC) often utilizes serum tumor markers. Although the most commonly used tumor marker in clinical practice, alpha-fetoprotein (AFP) is not included in recent guidelines for diagnosing HCC. The overall performance characteristics of AFP as a tumor marker is viewed as insufficiently sensitive or specific. The diagnostic value of AFP specifically in nonalcoholic steatohepatitis (NASH) related HCC is unknown. We aimed to determine the utility of AFP testing in NASH-related HCC. Methods: Retrospective review of 737 HCC patients referred from 1993- 2011 to a single facility treating the majority of chronic liver disease in Hawaii. HCC was diagnosed histologically by percutaneous biopsy, liver biopsy at the time of surgery, or examination of the resected liver. Patients were classified according to HCC risk factors including NASH, hepatitis B and C infection, and alcohol-related. Other data collected included: demographics, ethnicity, presence of cirrhosis, tumor characteristics (size, number, vascular invasion), diabetes, hyperlipidemia, body mass index (BMI) and blood testing to calculate Model for End-Stage Liver Disease (MELD) score. Elevated AFP was defined as >20 ng/mL. Sensitivity of AFP was determined and compared between various subgroups. Results: Elevated AFP levels were detected in 64.3% of patients. AFP sensitivity was 47% for NASH-related HCC (n = 100), and 67.2% for HCC with viral or alcoholic risk factors (n = 637) (OR 0.43, 95% CI 0.28 - 0.66, p = 0.0001). Elevated AFP had higher sensitivity in females (71.9% vs. 61.8%, OR 1.58, 95% CI 1.1 - 2.27, p = 0.013), non-diabetics (67.4% vs. 57.2%, OR 0.65, 95% CI 0.47 - 0.89, p = 0.0093), and cirrhotics (67.1% vs. 56.8%, OR 1.55, 95% CI 1.10 - 2.19, p = 0.0012).AFP did not vary significantly with regard to hyperlipidemia or BMI. AFP was more sensitive in advanced disease including tumors > 5 cm, multiple tumors, or vascular invasion (all with p < 0.05). AFP did not vary with MELD score. Conclusions: Normal AFP is common in NASH-related HCC. Better tumor markers may be needed to optimally screen and diagnose NASH-related HCC. Without more effective tumor markers, HCC detection relies heavily upon imaging and liver biopsy.

Keywords

Hepatocellular Cancer; Nonalcoholic Steatohepatitis; Alpha-Fetoprotein

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917. doi:10.1002/ijc.25516
[2]	El-Serag, H.B. and Mason, A.C. (1999) Rising incidence of hepatocellular carcinoma in the United States. New England Journal of Medicine, 340, 745-750. doi:10.1056/NEJM199903113401001
[3]	Gomaa, A.I., Khan, S.A., Toledano, M.B., Waked, I. and Taylor-Robinson, S.D. (2008) Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World Jour nal of Gastroenterology, 14, 4300-4308. doi:10.3748/wjg.14.4300
[4]	US National Institute of Health (2010) SEER Cancer Statistics Review 1975-2004. http://www.SEER.cancer.gov
[5]	Perz, J.F., Armstrong, G.L., Farrington, L.A., Hutin, Y.J. and Bell, B.P. (2006) The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology, 45, 529-538. doi:10.1016/j.jhep.2006.05.013
[6]	Hassan, M.M., Frome, A., Patt, Y.Z. and El-Serag H.B. (2002) Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. Journal of Clinical Gastroenterology, 35, 266-269. doi:10.1097/00004836-200209000-00013
[7]	El-Serag, H.B. (2004) Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology, 127, S27 S34. doi:10.1053/j.gastro.2004.09.013
[8]	Marrero, J.A., Fontana, R.J., Su, G.L., Conjeevaram, H.S., Emick, D.M. and Lok A.S. (2002) NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology, 36, 1349-1354. doi:10.1002/hep.1840360609
[9]	Starley, B.Q., Calcagno, C.J. and Harrison, S.A. (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology, 51, 1820-1832. doi:10.1002/hep.23594
[10]	Ong, J.P. and Younossi, Z.M. (2007) Epidemiology and natural history of NAFLD and NASH. Clinics in Liver Disease, 11, 1-16. doi:10.1016/j.cld.2007.02.009
[11]	Page, J.M. and Harrison, S.A. (2009) NASH and HCC. Clinics in Liver Disease, 13, 631-634. doi:10.1016/j.cld.2009.07.007
[12]	Baffy, G., Brunt, E.M. and Caldwell, S.H. (2012) Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. Journal of Hepatology, 56, 1384 1391. doi:10.1016/j.jhep.2011.10.027
[13]	Di Bisceglie, A.M., Sterling, R.K., Chung, R.T., Everhart, J.E., Dienstag, J.L., Bonkovsky, H.L., Wright, E.C., Ever son, G.T., Lindsay, K.L., Lok, A.S., Lee, W.M., Morgan, T.R., Ghany, M.G. and Gretch, D.R. (2005) Serum alpha fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. Journal of Hepatology, 43, 434-441. doi:10.1016/j.jhep.2005.03.019
[14]	Bruix, J. and Sherman, M. (2005) Management of hepatocellular carcinoma: An update. Hepatology, 42, 1208 1236. doi:10.1002/hep.20933
[15]	Gonzalez, S.A. and Keeffe, E.B. (2011) Diagnosis of heaptocellular carcinoma: role of tumor markers and liver biopsy. Clinics in Liver Disease, 15, 297-306. doi:10.1016/j.cld.2011.03.012
[16]	United Network for Organ Sharing (2011) Policy 3.6.4.4. www.unos.org
[17]	National Comprehensive Cancer Network (2010) NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. V.2.2010.
[18]	Edge, S.B. (2010) American Joint Committee on Cancer staging manual. 7th Edition, Springer, New York.
[19]	Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pul virenti, A., Bozzetti, F., Montalto, F., Ammaturna, M., Morabito, A. and Gennan, L. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. New England Journal of Medicine, 334, 693-699. doi:10.1056/NEJM199603143341104
[20]	Zhang, B.H., Yang, B.H. and Tang, Z.Y. (2004) Randomized controlled trial of screening for hepatocellular carcinoma. Journal of Cancer Research in Clinical Oncology, 130, 417-422. doi:10.1007/s00432-004-0552-0
[21]	Bruix, J., Sherman, M., Llovet, J.M., Beaugrand, M., Lencioni, R., Burroughs, A.K., Christensen, E., Pagliaro, L., Colombo, M. and Rodés J. (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona 2000 EASL conference. European Association for the Study of the Liver. Journal of Hepatology, 35, 421-430. doi:10.1016/S0168-8278(01)00130-1
[22]	Bruix, J. and Sherman, M. (2011) Management of hepatocellular carcinoma: An update. Hepatology, 53, 1020 1022. doi:10.1002/hep.24199
[23]	Torres, D.M. and Harrison, S.A. (2008) Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology, 134, 1682-1698. doi:10.1053/j.gastro.2008.02.077
[24]	Patwardhan, V., Paul, S., Corey, K.E., Mazhar, S.M., Richter, J.M., Thiim, M. and Chung R.T. (2011) Hepatocellular carcinoma screening rates vary by etiology of cirrhosis and involvement of gastrointestinal sub-specialists. Digestive Disease Sciences, 56, 3316-3322. doi:10.1007/s10620-011-1836-2
[25]	Davila, J.A., Morgan, R.O., Richardson, P.A., Du, X.L., McGlynn, K.A. and El-Serag, H.B. (2010) Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology, 52, 132 141. doi:10.1002/hep.23615